Thrombolytic therapy for wake-up stroke: A systematic review and meta-analysis.
ischemic stroke
perfusion-based imaging
tPA
thrombolysis
wake-up-stroke
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
06
03
2021
accepted:
21
03
2021
pubmed:
28
3
2021
medline:
13
8
2021
entrez:
27
3
2021
Statut:
ppublish
Résumé
According to evidence-based clinical practice guidelines, patients presenting with disabling stroke symptoms should be treated with intravenous tissue plasminogen activator (IV tPA) within 4.5 h of time last known well. However, 25% of strokes are detected upon awakening (i.e., wake-up stroke [WUS]), which renders patients ineligible for IV tPA administered via time-based treatment algorithms, because it is impossible to establish a reliable time of symptom onset. We performed a systematic review and meta-analysis of the efficacy and safety of IV tPA compared with normal saline, placebo, or no treatment in patients with WUS using imaging-based treatment algorithms. We searched MEDLINE, Web of Science, and Scopus between January 1, 2006 and April 30, 2020. We included controlled trials (randomized or nonrandomized), observational cohort studies (prospective or retrospective), and single-arm studies in which adults with WUS were administered IV tPA after magnetic resonance imaging (MRI)- or computed tomography (CT)-based imaging. Our primary outcome was recovery at 90 days (defined as a modified Rankin Scale [mRS] score of 0-2), and our secondary outcomes were symptomatic intracranial hemorrhage (sICH) within 36 h, mortality, and other adverse effects. We included 16 studies that enrolled a total of 14,017 patients. Most studies were conducted in Europe (37.5%) or North America (37.5%), and 1757 patients (12.5%) received IV tPA. All studies used MRI-based (five studies) or CT-based (10 studies) imaging selection, and one study used a combination of modalities. Sixty-one percent of patients receiving IV tPA achieved an mRS score of 0 to 2 at 90 days (95% confidence interval [CI]: 51%-70%, 12 studies), with a relative risk (RR) of 1.21 compared with patients not receiving IV tPA (95% CI: 1.01-1.46, four studies). Three percent of patients receiving IV tPA experienced sICH within 36 h (95% CI: 2.5%-4.1%; 16 studies), which is an RR of 4.00 compared with patients not receiving IV tPA (95% CI: 2.85-5.61, seven studies). This systematic review and meta-analysis suggests that IV tPA is associated with a better functional outcome at 90 days despite the increased but acceptable risk of sICH. Based on these results, IV tPA should be offered as a treatment for WUS patients with favorable neuroimaging findings.
Sections du résumé
BACKGROUND AND PURPOSE
According to evidence-based clinical practice guidelines, patients presenting with disabling stroke symptoms should be treated with intravenous tissue plasminogen activator (IV tPA) within 4.5 h of time last known well. However, 25% of strokes are detected upon awakening (i.e., wake-up stroke [WUS]), which renders patients ineligible for IV tPA administered via time-based treatment algorithms, because it is impossible to establish a reliable time of symptom onset. We performed a systematic review and meta-analysis of the efficacy and safety of IV tPA compared with normal saline, placebo, or no treatment in patients with WUS using imaging-based treatment algorithms.
METHODS
We searched MEDLINE, Web of Science, and Scopus between January 1, 2006 and April 30, 2020. We included controlled trials (randomized or nonrandomized), observational cohort studies (prospective or retrospective), and single-arm studies in which adults with WUS were administered IV tPA after magnetic resonance imaging (MRI)- or computed tomography (CT)-based imaging. Our primary outcome was recovery at 90 days (defined as a modified Rankin Scale [mRS] score of 0-2), and our secondary outcomes were symptomatic intracranial hemorrhage (sICH) within 36 h, mortality, and other adverse effects.
RESULTS
We included 16 studies that enrolled a total of 14,017 patients. Most studies were conducted in Europe (37.5%) or North America (37.5%), and 1757 patients (12.5%) received IV tPA. All studies used MRI-based (five studies) or CT-based (10 studies) imaging selection, and one study used a combination of modalities. Sixty-one percent of patients receiving IV tPA achieved an mRS score of 0 to 2 at 90 days (95% confidence interval [CI]: 51%-70%, 12 studies), with a relative risk (RR) of 1.21 compared with patients not receiving IV tPA (95% CI: 1.01-1.46, four studies). Three percent of patients receiving IV tPA experienced sICH within 36 h (95% CI: 2.5%-4.1%; 16 studies), which is an RR of 4.00 compared with patients not receiving IV tPA (95% CI: 2.85-5.61, seven studies).
CONCLUSIONS
This systematic review and meta-analysis suggests that IV tPA is associated with a better functional outcome at 90 days despite the increased but acceptable risk of sICH. Based on these results, IV tPA should be offered as a treatment for WUS patients with favorable neuroimaging findings.
Substances chimiques
Fibrinolytic Agents
0
Tissue Plasminogen Activator
EC 3.4.21.68
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2006-2016Informations de copyright
© 2021 European Academy of Neurology.
Références
Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: A guideline for healthcare professionals from the american heart association/american stroke association. Stroke. 2019;50:e344-e418.
Moradiya Y, Janjua N. Presentation and outcomes of "Wake-up strokes" In a large randomized stroke trial: Analysis of data from the international stroke trial. J Stroke Cerebrovasc Dis. 2013;22:e286-292.
Koton S, Tanne D, Bornstein NM, NASIS Investigators. Ischemic stroke on awakening: patients’ characteristics, outcomes and potential for reperfusion therapy. Neuroepidemiology. 2012;39:149-153.
Thomalla G, Simonsen CZ, Boutitie F, et al. Mri-guided thrombolysis for stroke with unknown time of onset. N Engl J Med. 2018;379:611-622.
Koga M, Yamamoto H, Inoue M, et al. Thrombolysis with alteplase at 0.6 mg/kg for stroke with unknown time of onset: a randomized controlled trial. Stroke. 2020;51:1530-1538.
Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: An updated pooled analysis of ecass, atlantis, ninds, and epithet trials. Lancet. 2010;375:1695-1703.
Elliott WJ. Circadian variation in the timing of stroke onset: a meta-analysis. Stroke. 1998;29:992-996.
Casetta I, Granieri E, Fallica E, la Cecilia O, Paolino E, Manfredini R. Patient demographic and clinical features and circadian variation in onset of ischemic stroke. Arch Neurol. 2002;59:48-53.
Lago A, Geffner D, Tembl J, Landete L, Valero C, Baquero M. Circadian variation in acute ischemic stroke: a hospital-based study. Stroke. 1998;29:1873-1875.
Marler JR, Price TR, Clark GL, et al. Morning increase in onset of ischemic stroke. Stroke. 1989;20:473-476.
Tsivgoulis G, Katsanos AH, Malhotra K, et al. Thrombolysis for acute ischemic stroke in the unwitnessed or extended therapeutic time window. Neurology. 2020;94:e1241-e1248.
Thomalla G, Boutitie F, Ma H, et al. Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: Systematic review and meta-analysis of individual patient data. Lancet. 2020;396:1574-1584.
Fink JN, Kumar S, Horkan C, et al. The stroke patient who woke up: Clinical and radiological features, including diffusion and perfusion MRI. Stroke. 2002;33:988-993.
Huisa BN, Raman R, Ernstrom K, et al. Alberta stroke program early ct score (aspects) in patients with wake-up stroke. J Stroke Cerebrovasc Dis. 2010;19:475-479.
Adeoye O, Hornung R, Khatri P, Kleindorfer D. Recombinant tissue-type plasminogen activator use for ischemic stroke in the united states: A doubling of treatment rates over the course of 5 years. Stroke. 2011;42:1952-1955.
Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
Wahlgren N, Ahmed N, Dávalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in stroke-monitoring study (sits-most): An observational study. Lancet. 2007;369:275-282.
Sterne JAC, Savović J, Page MJ, et al. Rob 2: A revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
Sterne JA, Hernán MA, Reeves BC, et al. Robins-i: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.
von Hippel PT. The heterogeneity statistic i(2) can be biased in small meta-analyses. BMC Med Res Methodol. 2015;15:35.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-1558.
Barreto AD, Martin-Schild S, Hallevi H, et al. Thrombolytic therapy for patients who wake-up with stroke. Stroke. 2009;40:827-832.
Hill MD, Kenney C, Dzialowski I, et al. Tissue window in stroke thrombolysis study (twist): a safety study. Can J Neurol Sci. 2013;40:17-20.
Manawadu D, Bodla S, Keep J, Jarosz J, Kalra L. An observational study of thrombolysis outcomes in wake-up ischemic stroke patients. Stroke. 2013;44:427-431.
Anaissie JE, Monlezun DJ, Siegler JE, et al. Intravenous tissue plasminogen activator for wake-up stroke: a propensity score-matched analysis. J Stroke Cerebrovasc Dis. 2016;25:2603-2609.
Barreto AD, Fanale CV, Alexandrov AV, et al. Prospective, open-label safety study of intravenous recombinant tissue plasminogen activator in wake-up stroke. Ann Neurol. 2016;80:211-218.
Urrutia VC, Faigle R, Zeiler SR, et al. Safety of intravenous alteplase within 4.5 hours for patients awakening with stroke symptoms. PLoS One. 2018;13:e0197714.
Armon C, Wainstein J, Gour A, et al. Ct-guided thrombolytic treatment of patients with wake-up strokes. eNeurologicalSci. 2019;14:91-97.
Sykora M, Kellert L, Michel P, et al. Thrombolysis in stroke with unknown onset based on non-contrast computerized tomography (trust ct). J Am Heart Assoc. 2020;9:e014265.
Morelli N, Rota E, Immovilli P, et al. Computed tomography perfusion-based thrombolysis in wake-up stroke. Intern Emerg Med. 2015;10:977-984.
Feil K, Reidler P, Kunz WG, et al. Addressing a real-life problem: Treatment with intravenous thrombolysis and mechanical thrombectomy in acute stroke patients with an extended time window beyond 4.5 h based on computed tomography perfusion imaging. Eur J Neurol. 2020;27:168-174.
Bai Q, Zhao Z, Fu P, et al. Clinical outcomes of fast mri-based thrombolysis in wake-up strokes compared to superacute ischemic strokes within 12 hours. Neurol Res. 2013;35:492-497.
Schwamm LH, Wu O, Song SS, et al. Intravenous thrombolysis in unwitnessed stroke onset: Mr witness trial results. Ann Neurol. 2018;83:980-993.
Zhao J, Zhao H, Li R, et al. Outcome of multimodal mri-guided intravenous thrombolysis in patients with stroke with unknown time of onset. Stroke Vasc Neurol. 2019;4:3-7.
Krebs S, Posekany A, Ferrari J, et al. Intravenous thrombolysis in wake-up stroke: Real-world data from the austrian stroke unit registry. Eur J Neurol. 2019;26:754-759.
Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342:1887-1892.
Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342:1878-1886.
Shrier I, Boivin JF, Steele RJ, et al. Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles. Am J Epidemiol. 2007;166:1203-1209.
Rothwell PM. External validity of randomised controlled trials: "To whom do the results of this trial apply?". Lancet. 2005;365:82-93.
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
Silva GS, Lima FO, Camargo ECS, et al. Wake-up stroke: clinical and neuroimaging characteristics. Cerebrovasc Dis. 2010;29:336-342.
Dankbaar JW, Bienfait HP, van den Berg C, et al. Wake-up stroke versus stroke with known onset time: clinical and multimodality ct imaging characteristics. Cerebrovasc Dis. 2018;45:236-244.
Ma H, Campbell BCV, Parsons MW, et al. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke. N Engl J Med. 2019;380:1795-1803.
Psychogios K, Magoufis G, Safouris A, et al. Eligibility for intravenous thrombolysis in acute ischemic stroke patients presenting in the 4.5-9 h window. Neuroradiology. 2020;62:733-739.
Moseley ME, Kucharczyk J, Mintorovitch J, et al. Diffusion-weighted mr imaging of acute stroke: Correlation with t2-weighted and magnetic susceptibility-enhanced mr imaging in cats. Am J Neuroradiol. 1990;11:423-429.
Hoehn-Berlage M, Eis M, Back T, Kohno K, Yamashita K. Changes of relaxation times (t1, t2) and apparent diffusion coefficient after permanent middle cerebral artery occlusion in the rat: Temporal evolution, regional extent, and comparison with histology. Magn Reson Med. 1995;34:824-834.
Venkatesan R, Lin W, Gurleyik K, et al. Absolute measurements of water content using magnetic resonance imaging: preliminary findings in an in vivo focal ischemic rat model. Magn Reson Med. 2000;43:146-150.
Barber PA, Demchuk AM, Zhang J, Buchan AM. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. Aspects study group. Alberta stroke programme early ct score. Lancet. 2000;355:1670-1674.